10亿!上市药企“豪投”生物创新药,收入囊中的产品线有哪些?

  • 上市药企,生物,创新药,产品线
  • 生物探索



4月7日,亿帆鑫富发布公告称,为实现业务转型升级,快速进入生物创新药业务领域,为实现药品制剂国际化战略奠定坚实基础,公司于4月6日,与Darga International Limited、Top Ceiling Investment Limited、Integral Investment-III Co.,Ltd.、Huang Yuliang、Tang Kaiyang、AURUM YEAR LIMITED签订《现金购买资产协议》,以现金100,068万元购买上述六方合计持有的 DHY&Co.,Ltd.(以下简称“DHY公司”)57,938,462股普通股股份,占DHY公司总股份的53.80%。


DHY公司有何实力?


据介绍,DHY公司是注册于英属维尔京群岛的公司,主要子公司为上海健能隆。健能隆于2004年创立,致力于开发创新大分子生物药。健能隆目前已建立了两个新药研发平台(DiKineTM双分子平台,ITabTM免疫抗体平台),并成功开发了一系列处于临床和临床前阶段的创新型大分子生物药。


公司第三代创新药贝格司亭(F-627,长效G-CSF-Fc)进入全球三期临床和中国三期临床,自主首创新药普罗纳亭(F-652,白介素-22-Fc)已进入两项国际二期临床和中国一期临床,肿瘤免疫双特异性抗体新药A-337将进入国际一期临床,长效生长激素F-899将进入临床申报。这些药物主要用于肿瘤、神经性疾病、肝病和老年性疾病等的治疗。公司已申请发明专利逾80件,其中已获专利授权33件、专利许可5件。

在研项目研发进展如下:





公告显示,健能隆开创的新一代长效G-CSF药物贝格司亭是首个中国生物新药研发公司经美国FDA同意在美欧开展国际多中心临床研究的第一个创新生物药,其国际三期临床将在全球15个国家和地区的医学中心开展; 同时,普罗纳亭的两个罕见病临床二期在半年内获得美国FDA同意开展。




2016年,逐步切入大分子生物药领域


4月5日,亿帆鑫富更新了2015 年年度报告,公司2015年营业收入24.35亿元,同比增长44.51 %;归属于上市公司股东的净利润3.61亿元,同比增长51.56 %;基本每股收益0.82元,同比下降5.75%。2016年第一季度预计盈利12,627.44 万元–15,152.92 万元。


年报指出,2016年公司的重点工作包括继续开展产业链的并购重组:以“保旧创新”为准则,在药品制剂业务板块,继续拓展与巩固以专业性、专科性及治疗型为主的产品线建设,并逐步切入到大分子生物药领域,同步实现产品国际化,加速公司转型升级。


此次公告中,亿帆鑫富表示,本次交易若顺利完成,公司将能借力DHY公司在生物药领域领先的研发团队、创新型研发与生产平台及研发成果,在提高公司整体研发实力与创新能力的基础上,快速进入大分子生物创新药业务领域。




This link:http://www.chemcd.com/news/26653.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.